AACR PATIENT ADVOCATE FORUM

EXPLORING A NEW GENERATION OF PATIENT-CENTRIC CANCER CLINICAL TRIALS

Speakers

PATRICIA M. LORUSSO, DO, PHD (HC), FAACR

AACR PRESIDENT 2024-2025
Professor of Medicine
Chief of the Early Phase Clinical Trials Program
Yale University
Associate Center Director of Experimental Therapeutics
Yale Cancer Center
New Haven, CT

Dr. LoRusso is a nationally recognized expert in developing new cancer drugs through clinical trials. Dr. LoRusso has pioneered significant advances in medical oncology, drug development, and early phase clinical trials for her work at Wayne State University's Barbara Karmanos Cancer Institute as director of both the phase I Clinical Trials Program and of the Eisenberg Center for Experimental Therapeutics.

Throughout her career, Dr. LoRusso has received numerous honors and awards, including the World Affairs Council of Connecticut Luminary Award (2018); Crain's Detroit Business Heroes of Healthcare Award (2008); Marygrove College Distinguished Alumni Award (2008); Top Doctors honoree (2007, 2009, 2011-2013, 2018); and the Michigan Society for Medical Research Bennett J. Cohen Educational Leadership Award for Medical Research (2004). Dr. LoRusso received an honorary PhD from Michigan State University in 2015 and was elected as a fellow of the American Society of Clinical Oncology in 2022.

Dr. LoRusso received her BS from Marygrove College, her DO from Michigan State University, and an honorary PhD from Michigan State University in 2015. Prior to her appointment at the Yale School of Medicine, she served in numerous leadership roles at Wayne State University's Barbara Ann Karmanos Cancer Institute, including as director of the Phase I Clinical Trials Program and director of the Eisenberg Center for Translational Therapeutics.

DAVID A. TUVESON, MD, PHD, FAACR

AACR PAST PRESIDENT 2020-2021
Director and Roy J. Zuckerberg Professor of Cancer Research
Cold Spring Harbor Laboratory (CSHL) Cancer Center
Harvard T.H. Chan School of Public Health
Cold Spring Harbor, NY

Dr. Tuveson is the director of the Cold Spring Harbor Laboratory Cancer Center, where he is also the Roy J. Zuckerberg professor of cancer research. Additionally, he is the chief scientist for the Lustgarten Foundation, a medical staff affiliate at Memorial

Sloan Kettering Cancer Center, and serves on the Board of Scientific Advisors of the National Cancer Institute. Dr. Tuveson is a world-renowned physician-scientist whose basic and translational research focuses on increasing our understanding of the biology of pancreatic cancer and on identifying and testing new approaches for diagnosing and treating the disease in preclinical and clinical settings. An AACR member since 2003, Dr. Tuveson is a scientific editor of the AACR journal Cancer Discovery, a member of the Scientific Advisory Committee for Stand Up To Cancer, and a Fellow of the AACR Academy. He is also the AACR President for 2021-22.

LAURA VAN 'T VEER, PHD

Angela and Shu Kai Chan Endowed Chair in Cancer Research
Co-leader, Breast Oncology Program
Helen Diller Family Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA

Dr. van 't Veer is a world-renowned Molecular Biologist and inventor of MammaPrint®. Her research focuses on personalized medicine to advance patient management based on knowledge of the genetic make-up of the tumor as well as the genetic make-up of the patient. Dr. van 't Veer is the Biomarker Committee Chair for the Foundation of NIH sponsored multicenter adaptive clinical trial I-SPY 2, overseeing the processes for FDA-IDE biomarker usage and qualifying biomarker companion diagnostic testing. She served 2010-2014 as Board member of the American Association of Cancer Research. She has over 230 peer-reviewed scientific articles and is co-inventor of 6 patents.

Dr. van 't Veer received undergraduate training in biology and a master of science in molecular oncology (1984) at the University of Amsterdam in the Netherlands. She earned her PhD in Medicine at the University of Leiden and then completed two postdoctoral fellowships, first at the Cancer Center of Harvard Medical School and Massachusetts General Hospital in Boston (1989-1991), followed by the Division of Molecular Carcinogenesis at The Netherlands Cancer Institute (1992-1993).

Dr. van 't Veer moved to UCSF as Professor of Laboratory Medicine in 2010 and assumed leadership of the Bay Area Breast Cancer SPORE and the BOP. In 2011 she assumed leadership of the Athena Breast Health Network at UCSF. She holds the Angela and Shu Kai Chan Endowed Chair in Cancer Research.

Moderator

ANNA D. BARKER, PHD, FAACR

Founder and Chair, AACR Scientist↔Survivor Program®
Chief Strategy Officer, Ellison Institute of Technology
Distinguished Visiting Fellow, Complex Adaptive Systems, Arizona State University

Dr. Barker is the founder and chair of the AACR Scientist↔Survivor Program® and chief strategy officer of the Lawrence J. Ellison Institute for

Transformative Medicine and distinguished visiting fellow at Arizona State University. She develops information-based strategies through internal research and engagement of networks of leading experts in medicine, science, and engineering to solve complex problems in cancer and other diseases. Previously, Dr. Barker served as the principal deputy director of the National Cancer Institute (NCI) where she led the development of Foundational platforms (Clinical Proteomics and National Cancer Nanotechnology Centers) and national programs (e.g., TCGA, Physical-Sciences Oncology Centers) to support the emerging concept of precision medicine. Hallmarks of these strategic innovative programs were networks of global institutions, team science and publicly available data.

Post NCI, Dr. Barker served as director of Transformative Healthcare Networks, co-director of Complex Adaptive Systems -Biomedicine (CAS) and professor of practice, School of Life Sciences at Arizona State University (ASU), where she maintains a courtesy academic appointment. At ASU, she employed CAS approaches through “knowledge networks” to enable progress in areas ranging from clinical trial designs to biomarker discovery and applying concepts from the physical sciences to fundamentally understand and control complex diseases such as cancer.

Dr. Barker also spent several years at Battelle Memorial Institute, a nonprofit transdisciplinary research organization, where she progressed from a research scientist to serve in several senior executive roles. She has received numerous awards for her contributions to cancer research, cancer patients and patient advocates, professional organizations, and the ongoing national effort to prevent and cure cancer. Dr. Barker received her doctoral degree from the Ohio State University.